This CME activity is provided by the American Society for Clinical Pathology (ASCP):
Update on Immuno-Oncology Biomarkers
This 1 hour, interactive, online CME/CMLE module will help pathologists, laboratory professionals, and other members of the cancer care team gain deeper scientific knowledge in immuno-oncology (IO) and keep up with the rapidly evolving science of IO biomarkers including IO biomarker testing, tumor mutational burden, PD-L1 testing and interpretation, and the use of checkpoint inhibitors for treatment.
Don't miss this free CME activity titled:
Overcoming Common Barriers Around the Application of Immuno-Oncology in Community Settings
This CME multidisciplinary panel discussion will feature interactive problem-based learning with a focus on common barriers to implementing and delivering IO in community pathology settings, including a practical discussion around overcoming some of those barriers. Some areas identified as needing pathology leadership and support are evidence-based QI planning for disease-specific IO procedures and developing consistent protocols and workflows related to cancer diagnosis and the use of IO treatments.
In the month of April 2019, the FDA announced the following new or expanded drug approvals:
FDA approved pembrolizumab (KEYTRUDA, Merck & Co. Inc.) plus axitinib for the first-line treatment of patients with advanced renal cell carcinoma (RCC). April 19, 2019
FDA granted accelerated approval to erdafitinib (BALVERSA, Janssen Pharmaceutical Companies) for patients with locally advanced or metastatic urothelial carcinoma, with susceptible FGFR3 or FGFR2 genetic alterations, that has progressed during or following platinum-containing chemotherapy, including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy. April 12, 2019
FDA approved pembrolizumab (KEYTRUDA, Merck Inc.) for the first-line treatment of patients with stage III non-small cell lung cancer (NSCLC) who are not candidates for surgical resection or definitive chemoradiation or metastatic NSCLC. Patients’ tumors must have no EGFR or ALK genomic aberrations and express PD-L1 (Tumor Proportion Score [TPS] ≥1%) determined by an FDA-approved test. April 11, 2019
i-PARiHS (Promoting Action on Research Implementation) framework for the implementation of knowledge into practice
The Promoting Action on Research Implementation in Health Services, or PARIHS framework, was first published in 1998. A revised version of the framework, called the integrated or i-PARIHS framework, was proposed in 2016 by Harvey and Kitson.
The main reasons for re-visiting the original PARIHS framework included:
The authors propose adding a new construct termed ‘recipient’. The core constructs of the i-PARIHS framework are facilitation, innovation, recipients and context, with facilitation represented as the active element assessing, aligning and integrating the other three constructs.
Read more about the i-PARiHS framework here:
Harvey G, Kitson A. PARIHS revisited: from heuristic to integrated framework for the successful implementation of knowledge into practice. Implement Sci. 2016;11:33. Published 2016 Mar 10. doi:10.1186/s13012-016-0398-2
The Centers for Medicare & Medicaid Services (CMS) include accredited CME as an improvement activity in the Merit-Based Incentive Payment System (MIPS) of the Quality Payment Program (QPP). These improvement activities are included in the current (PY2018) Clinical Practice Improvement Activities and are listed as Completion of An Accredited Safety or Quality Improvement Program (Activity ID IA_PSPA_28) under the Patient Safety and Practice Assessment category on the QPP website.
CME activities that meet the criteria for improvement activities in the Merit-Based Incentive Payment System (MIPS) of QPP must:
More information about "CME for MIPS" is available from the ACCME website: https://www.accme.org/cme-for-mips
The ACCME has also provided a step-by-step guide around CME for MIPS
The following description is taken from the QPP website: https://qpp.cms.gov/mips/improvement-activities
Completion of an Accredited Safety or Quality Improvement Program
Completion of an accredited performance improvement continuing medical education program that addresses performance or quality improvement according to the following criteria: • The activity must address a quality or safety gap that is supported by a needs assessment or problem analysis, or must support the completion of such a needs assessment as part of the activity; • The activity must have specific, measurable aim(s) for improvement; • The activity must include interventions intended to result in improvement; • The activity must include data collection and analysis of performance data to assess the impact of the interventions; and The accredited program must define meaningful clinician participation in their activity, describe the mechanism for identifying clinicians who meet the requirements, and provide participant completion information.
Subcategory Name: Patient Safety And Practice Assessment
Activity ID: IA_PSPA_28
This free CME activity is available from ASCP.org
Implementing Immuno-Oncology Education in a Community Cancer Center
This CME panel discussion features faculty and members of the inter-professional team involved in an Implementation Science (IS) pilot program at a community cancer center. Panelists will discuss key findings related to the challenges and barriers they had to overcome in implementing immuno-oncology education, lessons learned, and plans for sustaining changes and improvements.
The following free CME activity is available on myCME.com:
Applying the Latest Evidence to Improve Care for Patients with HR+/HER2- Metastatic Breast Cancer
The care of patients with metastatic breast cancer is becoming increasingly complex and there is a growing need to ensure that members of the cancer care team are working together to provide the best possible care that driven by the latest evidence. Continuing education can ensure that clinicians are employing effective models of team-based care coordination and implementing systems-based processes that are designed to improve the management of patients with HR+/HER2- metastatic breast cancer.
There is a great article on Medium.com titled, "Tools for Systems Thinkers: The 6 Fundamental Concepts of Systems Thinking." The author outlines six critical building blocks for developing a systems perspective:
Read more about complex adaptive systems thinking.
The original guidelines for HER2 testing in breast cancer were jointly published by ASCO and CAP over 10 years ago, updated in 2013, and updated again in 2018.
The Focused Update of the “Human Epidermal Growth Factor Receptor 2 (HER2) Testing in Breast Cancer” clinical practice guideline has been developed by an expert panel of pathologists and oncologists and issued by the American Society of Clinical Oncology (ASCO) and the College of American Pathologists (CAP) to address new information made available since the guideline’s previous update in 2013.
The 2018 Focused Update addresses uncommon clinical scenarios and improves clarity, particularly for infrequent HER2 test results that are of uncertain biologic or clinical significance. Some of the highlights include:
Published May 30, 2018 as an early online release in Archives of Pathology & Laboratory Medicine.
At the American Association for Cancer Research (AACR) meeting, several major updates in lung cancer immunotherapy studies were announced and thee articles were concurrently published in the NEJM:
Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
April 16, 2018
Sign up to receive updates: